ARH460-23: YAR will not begin Phase I testing of ARH460-23, which it had planned to begin in the first half of the year. YAR said it will instead focus on devel

Arius Research Inc. (CDNX:YAR), Toronto, Ontario Product: ARH460-23 Business: Antibodies, Cancer Therapeutic category: Antibody Target: Tumor tissue Description: Murine monoclonal antibody Indication:...